Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBAI20 adjuvanted hepatitis B vaccine in hepatitis B-naive adults and prior vaccine non-responders
NL-OMON41999Active, not recruiting
- Sponsor
- CyTuVax
- Start
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of HBAI20 adjuvanted hepatitis B vaccine in hepatitis B (HBV), sponsored by CyTuVax. Primary endpoint: Number and intensity of local and systemic adverse reactions. Started Oct 2017; status: active, not recruiting.
02
Drugs
HBAI20 adjuvanted hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NL-OMON41999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41999.